|Analyst says Incyte's pipeline makes it attractive takeover candidate|
|Tuesday, 15 May 2012 06:26|
Pfizer (NYSE: PFE) looks like it is getting its next blockbuster approved after an advisory panel voted 8-2 recommending approval of its rheumatoid arthritis drug tofacitinib and Goldman is reportedly more bullish about INCY due to the significant derisking of Incyte's key pipeline asset LY3009104. In addition, INCY has seen a strong launch of Jakafi-- an indicated for treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post–polycythemia vera myelofibrosis and post–essential thrombocythemia myelofibrosis.
"104's potential was validated with the positive FDA panel vote this past week on Pfizer’s tofacitinib," the firm said.Goldman also sees Incyte as a more attractive M&A target given it has a marketed drug and a potential blockbuster pipeline asset.
Shares could be worth up to $37 in a takeover, Goldman Sachs estimates.
We note that this stock is highly shorted and share purchases by insiders have been on the rise.
The BioMedReports FDA Calendar shows a few upcoming milestones for the company over the next two years including news that a randomized Phase II trial of ruxolitinib in combination with capecitabine for patients with recurrent or treatment refractory metastatic pancreatic cancer (the RECAP trial) is expected to enroll approximately 130 patients by the end of 2012. Results from the RESPONSE trial are expected in the second half of 2013.